Nicotinamide in specialized capsules for post-COVID syndrome (PCS)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observation-based approach evaluates whether a lower-intestine–released nicotinamide formulation (CICR-NAM) improves outcomes for adults with post-COVID syndrome who have low serum tryptophan. Participants take one 500 mg CICR-NAM tablet daily for up to about four months as part of their PCS care at the Kiel outpatient clinic, alongside standard therapy. The program builds on prior data suggesting nicotinamide may support energy metabolism and gut microbial balance linked to PCS symptoms. The study leverages existing clinical pathways and excludes individuals with certain medical conditions or high gastric pH–related risks to CICR-NAM release. The trial is conducted at University Hospital Schleswig-Holstein in Kiel under the lead sponsorship of the same institution.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* all sexes;
* minimum age 18 years; no upper age limit;
* post-COVID syndrome (PCS)
* serum tryptophan \<55 µmol/L (UKSH reference range: 48-109 µmol/L);
* participation in the therapy groups of the PCS outpatient clinic at UKSH Campus Kiel.

Exclusion Criteria:

* Known allergies or intolerances to any component of CICR-NAM;
* inability to provide informed consent;
* pregnancy or breastfeeding;
* severe comorbid disease (especially renal insufficiency, uncontrolled autoimmune diseases, liver disease, or malignancy);
* long-term use of higher doses of medications that raise gastric pH (for example proton pump inhibitors, H2 receptor antagonists, or antacids), as an increase in pH toward approximately 7 may cause premature release of nicotinamide from CICR-NAM;
* use of supplements containing more than 20 mg nicotinamide, nicotinamide riboside, nicotinamide mononucleotide, nicotinic acid, or NAD+ per daily dose.

Where it's running

• University Hospital Schleswig Holstein
  Kiel, Germany Recruiting

Study contacts

• Study coordinator: Lennart Reinke, Dr. med.
• Email: lennartmichel.reinke@uksh.de
• Phone: +49 431 500-22200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tralokinumab for moderate-to-severe atopic dermatitis affecting the genital area

  This trial will try tralokinumab in adults with moderate-to-severe atopic dermatitis involving the genital region to see if it improves genital symptoms and quality of life.

  Recruiting at 2 sites University Hospital Schleswig-Holstein · Augsburg, München and 1 other locations · NCT07444801

• Prevention in PD: a six-month lifestyle program for PD and RBD

  This study tests whether a six-month, structured lifestyle program combining exercise, Mediterranean diet, sleep guidance, and cognitive training helps people with Parkinson’s disease or REM sleep behavior disorder stick to healthier habits.

  Recruiting University Hospital Schleswig-Holstein · Kiel · NCT07297407

• Oral ileum-targeted controlled-release nicotinic acid to reverse prediabetes

  This trial tests whether taking a daily oral ileum-targeted controlled-release nicotinic acid pill for 26 weeks can help adults with prediabetes return to normal blood sugar and remains safe.

  Recruiting at 2 sites Phase 2 University Hospital Schleswig-Holstein · Berlin and 5 other locations · NCT07286747

• Early mirikizumab versus azathioprine for newly diagnosed moderate-to-severe ulcerative colitis

  This trial will test whether starting mirikizumab right away instead of beginning with azathioprine helps people newly diagnosed with moderate-to-severe ulcerative colitis who did not respond well to mesalazine and steroids.

  Recruiting Phase 4 University Hospital Schleswig-Holstein · Kiel · NCT07235904

• Kidney and heart prevention program after preeclampsia

  This program will see if follow-up care plus a biobank can help identify and manage long-term kidney and heart risks for women who had preeclampsia, HELLP, eclampsia, or pregnancy-related kidney disease.

  Recruiting University Hospital Schleswig-Holstein · Kiel · NCT07151339

• Three-fraction prostate radiosurgery for localized prostate cancer

  This trial will test whether giving prostate radiosurgery in three high-dose sessions is safe and causes fewer late urinary and bowel side effects for men with localized, low- to intermediate-risk prostate cancer.

  Recruiting at 4 sites University Hospital Schleswig-Holstein · Frankfurt am Main, Hesse and 5 other locations · NCT06914544

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.